PMID- 19895612
OWN - NLM
STAT- MEDLINE
DCOM- 20100629
LR  - 20220419
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 148
IP  - 4
DP  - 2010 Feb
TI  - An increased frequency of 13q deletions detected by fluorescence in situ 
      hybridization and its impact on survival in children and adolescents with Burkitt 
      lymphoma: results from the Children's Oncology Group study CCG-5961.
PG  - 600-10
LID - 10.1111/j.1365-2141.2009.07967.x [doi]
AB  - Burkitt lymphoma (BL), an aggressive B-cell malignancy, is often curable with 
      short intensive treatment regiments. Nearly all BLs contain rearrangements of the 
      MYC/8q24 region; however, recent cytogenetic studies suggest that certain 
      secondary chromosomal aberrations in BL correlate with an adverse prognosis. In 
      this multi-centre study, the frequency and impact on clinical outcome of del(13q) 
      and +7 in addition to MYC rearrangements as detected by fluorescence in situ 
      hybridization (FISH) in children and adolescents with intermediate and high-risk 
      BL registered on Children's Cancer Group study CCG-5961 were investigated. 
      Analysis with 13q14.3 and 13q34 loci specific probes demonstrated deletions of 
      13q in 38/90 (42%) cases. The loss of either 13q14.3 or 13q34 alone occurred in 
      14% and 8% respectively, while 20% exhibited loss of both regions. Gain of 
      chromosome 7 was observed in 7/68 (10%) cases and MYC rearrangements were 
      detected in 84/90 (93%). Prognostic analysis controlling for known risk factors 
      demonstrated that patients exhibiting loss of 13q, particularly 13q14.3, had a 
      significant decrease in 5-year overall survival (77% vs. 95%, P = 0.012). These 
      observations indicate that del(13q) occurs in childhood BL at frequencies higher 
      than previously detected by classical cytogenetics and underscores the importance 
      of molecular cytogenetics in risk stratification.
FAU - Nelson, Marilu
AU  - Nelson M
AD  - Human Genetics Laboratories, Munroe Meyer Institute for Genetics and 
      Rehabilitation, University of Nebraska Medical Center, 985440 Nebraska Medical 
      Center, Omaha, NE 68198, USA.
FAU - Perkins, Sherrie L
AU  - Perkins SL
FAU - Dave, Bhavana J
AU  - Dave BJ
FAU - Coccia, Peter F
AU  - Coccia PF
FAU - Bridge, Julia A
AU  - Bridge JA
FAU - Lyden, Elizabeth R
AU  - Lyden ER
FAU - Heerema, Nyla A
AU  - Heerema NA
FAU - Lones, Mark A
AU  - Lones MA
FAU - Harrison, Lauren
AU  - Harrison L
FAU - Cairo, Mitchell S
AU  - Cairo MS
FAU - Sanger, Warren G
AU  - Sanger WG
LA  - eng
GR  - U10 CA098413/CA/NCI NIH HHS/United States
GR  - U10 CA098543/CA/NCI NIH HHS/United States
GR  - U10 CA098543-01/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20091104
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Burkitt Lymphoma/drug therapy/*genetics/pathology
MH  - Child
MH  - Child, Preschool
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 13/*genetics
MH  - Epidemiologic Methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Male
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC2921871
MID - NIHMS163764
EDAT- 2009/11/10 06:00
MHDA- 2010/06/30 06:00
PMCR- 2011/02/01
CRDT- 2009/11/10 06:00
PHST- 2009/11/10 06:00 [entrez]
PHST- 2009/11/10 06:00 [pubmed]
PHST- 2010/06/30 06:00 [medline]
PHST- 2011/02/01 00:00 [pmc-release]
AID - BJH7967 [pii]
AID - 10.1111/j.1365-2141.2009.07967.x [doi]
PST - ppublish
SO  - Br J Haematol. 2010 Feb;148(4):600-10. doi: 10.1111/j.1365-2141.2009.07967.x. 
      Epub 2009 Nov 4.